Matricelf is a biotechnology pioneer advancing the future of personalized medicine. We develop cutting-edge platforms for autologous 3D tissue engineering, enabling patient-specific regenerative therapies for a wide range of medical conditions.
Matricelf’s journey begins with spinal cord injury—one of the most devastating and currently incurable neurological conditions. By focusing first on restoring motor and sensory function through a curative, autologous neural tissue transplant, we aim to redefine the standard of care for paralyzed patients and unlock broader regenerative potential.
Founded in 2019 by Professor Tal Dvir at Tel Aviv University’s Laboratory for Tissue Engineering and Regenerative Medicine, Matricelf is transforming the way we approach treatment—by engineering tissues uniquely tailored to each patient.
